| Bioactivity | M4284 is a selective and orally active biphenyl mannoside FimH antagonist. M4284 has activities against different UPEC (Urinary tract infections (UTI) caused by uropathogenic E. coli) strains in different host genetic backgrounds and gut microbial community contexts[1]. | ||||||||||||
| Target | IC50: FimH | ||||||||||||
| In Vivo | M4284 (oral administration; 100 mg/kg; 3 doses) can reduces UTI89 levels in the gut and urinary tracts of mice that are concurrently colonized with UTI89 in the gut and bladder. And treating mice with additonal M4284 doses further reduces the UTI89 population and the number of UPEC is lower in M4284-treated mice after termination of treatment[1]. Animal Model: | ||||||||||||
| Name | M4284 | ||||||||||||
| CAS | 1373346-85-0 | ||||||||||||
| Formula | C23H28N2O8 | ||||||||||||
| Molar Mass | 460.48 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Schaeffer EM, et al.Selective Depletion of Uropathogenic E. coli from the Gut by a FimH Antagonist.SelectivJ Urol. 2018 Apr;199(4):874-875. |